ArticleCureus2026
Complete Response to Chemo-Immunotherapy in Recurrent Unresectable Tracheal Squamous Cell Carcinoma: A Case Report.
Article in Cureus, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Primary malignant tumors of the trachea are rare, with squamous cell carcinoma (SCC) being the most frequent subtype. Due to limited data, optimal systemic therapy for unresectable or recurrent cases remains undefined. We report a case of recurrent primary tracheal SCC achieving durable complete remission with immune checkpoint inhibitor (ICI)-based combination chemotherapy. A 73-year-old man with a history of resected lung cancer was incidentally diagnosed with tracheal SCC. Following bronchoscopic tumor debulking, he underwent concurrent chemoradiotherapy. Recurrence with pulmonary metastases occurred 4 months later. He was treated with four cycles of pembrolizumab plus nab-paclitaxel and carboplatin, followed by pembrolizumab maintenance. Complete radiologic remission was achieved and sustained for over two years. This case highlights the potential of ICI-based regimens, widely used in non-small cell lung cancer, as a promising option for recurrent tracheal SCC. Multidisciplinary approaches incorporating immunotherapy may offer meaningful benefit in this rare malignancy.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.